Protocol Ledger

NCT05939414 · Phase III · RECRUITING

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Interventional Phase III clinical trial protocol NCT05939414 sponsored by Novartis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-12 Enrollment: 450 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05939414
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)450 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05939414
Protocol FieldVerified Registry Value
NCT IdentifierNCT05939414
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment450 participants (ESTIMATED)
Registered Start Date2024-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05939414
Hospital Research SiteLocationSite Profile
VA Palo Alto Health Care SystemPalo Alto, CAOpen Hospital Dossier ->
Stanford Health Care and Stanford Cancer InstituteStanford, CAOpen Hospital Dossier ->
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI